Vancomycin serum concentrations in pediatric oncologic/hematologic intensive care patients

Vancomycin serum concentrations in pediatric oncologic/hematologic intensive care patients

Autor Silva, Dáfne Cardoso Bourguignon da Autor UNIFESP Google Scholar
Seixas, Gláucia Toribio Finoti Autor UNIFESP Google Scholar
Araujo, Orlei Ribeiro de Autor UNIFESP Google Scholar
Arduini, Rodrigo Genaro Autor UNIFESP Google Scholar
Carlesse, Fabianne Altruda de Moraes Costa Autor UNIFESP Google Scholar
Petrilli, Antonio Sergio Autor UNIFESP Google Scholar
Instituição Universidade Federal de São Paulo (UNIFESP)
Resumo BACKGROUND: Usual treatment regimens with vancomycin often fail to provide adequate serum levels in patients with severe infections. METHODS: Retrospective analysis of vancomycin trough serum measurements. The following parameters were calculated by Bayesian analysis: vancomycin clearance, distribution volume, and peak estimated concentrations. The area under the concentration curve (AUC) (total daily dose/24 h clearance of vancomycin) was used to determine the effectiveness of treatment through the ratio of AUC/minimum inhibitory concentration (MIC) above 400, using MIC = 1 µg/mL, based on isolates of Staphylococci in cultures. RESULTS: Sixty-one vancomycin trough measurements were analyzed in 31 patients. AUC/MIC > 400 was obtained in 34 out of 61 dosages (55.7%), but the mean vancomycin dose required to achieve these levels was 81 mg/kg/day. In cases where the usual doses were administered (40-60 mg/kg/day), AUC/MIC > 400 was obtained in nine out of 18 dosages (50%), in 13 patients. Trough serum concentrations above 15 mg/L presented a positive predictive value of 100% and a negative predictive value of 71% for AUC/MIC > 400. CONCLUSION: Higher than usual vancomycin doses may be required to treat staphylococcal infections in children with oncologic/hematologic diseases. Since the best known predictor of efficacy is the AUC/MIC ratio, serum trough concentrations must be analyzed in conjunction with MICs of prevalent Staphylococci and pharmacokinetic tools such as Bayesian analysis.
Assunto Immunosuppression
Drug resistance
Anti-bacterial agents
Idioma Inglês
Data 2012-08-01
Publicado em Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 16, n. 4, p. 361-365, 2012.
ISSN 1413-8670 (Sherpa/Romeo, fator de impacto)
Editor Brazilian Society of Infectious Diseases
Extensão 361-365
Direito de acesso Acesso aberto Open Access
Tipo Artigo
Web of Science WOS:000307527400009
SciELO S1413-86702012000400009 (estatísticas na SciELO)

Mostrar registro completo

Arquivos deste item

Nome: S1413-86702012000400009.pdf
Tamanho: 230.3Kb
Formato: PDF

Este item aparece na(s) seguinte(s) coleção(s)